US Patent Issued to Bristol-Myers Squibb on Sept. 23 for "Methods of treatment or prevention of immune responses and inflammatory diseases with antagonistic CD40 monoclonal antibodies" (American, Canadian Inventors)

ALEXANDRIA, Va., Sept. 23 -- United States Patent no. 12,419,953, issued on Sept. 23, was assigned to Bristol-Myers Squibb Co. (Princeton, N.J.).

"Methods of treatment or prevention of immune responses and inflammatory diseases with antagonistic CD40 monoclonal antibodies" was invented by Aaron Yamniuk (Vancouver, Canada), Mary Struthers (Edison, N.J.), Stanley R. Krystek Jr. (Ringoes, N.J.), Akbar Nayeem (Newtown, Pa.) and Ginger Rakestraw (Somerville, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domai...